Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.
A carbohydrate called heparan sulfate, found on cell surfaces, may help the new coronavirus infects cells.
A recent study also found that having a higher body mass index was associated with a higher risk of fatty liver disease.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
A recent study of veterans found that antiretroviral treatment was not associated with a mitigated dementia risk.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
Compared with unvaccinated women, the risk among women vaccinated before age 17 dropped by almost 90%.
A clinical trial found no difference in outcomes based on whether participants switching to Cabenuva first took oral meds for four weeks.
A mid-stage trial of the experimental drug islatravir plus Pifeltro did not see notable shifts in measures of kidney function.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.